SCOTTISH LIFE SCIENCE COMPANY DEVELOPS COVID-19 ANTIBODY SCREENING TRIALS TO AID QUEST FOR VACCINE DEVELOPMENT

• Patient blood serum tests could reach 18000 per day using the ArrayPlex high-throughput biologics screening assay.

• R&D tests use synthetic COVID-19 proteins printed on “biological microchips” alongside entire the human proteome

• Collaborative partnership calls for diagnostic and life science companies with capabilities to implement their novel infectious sample screening technology to come forward

EDINBURGH, UK – Tuesday 5^th May 2020: Arrayjet Limited, the Scottish-based bio-printing technology specialist for the life sciences industry, has re-purposed its in-house antibody screening technology to create a population-scale diagnostic programme that will help scientists better understand the behaviour of the Covid-19 virus and further the rapidity of a global vaccination programme. 

For this screening platform, an international collaborative partnership has been formed between Arrayjet and CDI Laboratories, a US-based proteomics company, located in Baltimore, Maryland and Mayaguez, Puerto Rico, which specialise in advancing proteomic research and development.

The team are using Arrayjet’s antibody screening technology ArrayPlex, and optimised reagents from CDI, to print thousands of droplets of synthetically made COVID-19 viral proteins on “biological microchips”. The microchips are then used to profile the immune responses of large groups of patients by accurately printing tiny droplets (0.0000001 ml) of their blood serum on top of the virus proteins. The platform provides an automated antibody profiling test using the serum of 18,000 patients per instrument every 24 hours.

Iain McWilliam, CEO, Arrayjet, comments;

“As disease control and vaccine development measures continue apace across the globe, there is a requirement to understand and monitor large cohorts of test populations to identify which individuals are developing immunity. Our ability to mass screen 18000 patients, per instrument, every 24 hours with ArrayPlex will help provide datasets to epidemiologists and virologists to support their work understanding the complexities of virulence within the population.”

Whilst initial trials of the screening process have been successful, the collaborators now need to engage with other companies and research centres to screen infectious serum samples. This is a specialised diagnostic field and by joining efforts within the global life sciences community, Arrayjet and CDI will further advance the roll-out of their programme.

Arrayjet’s technology ArrayPlex, can reveal if a person has an antibody signature in their blood which indicates that they have already been exposed to SARS-Cov-2.

ArrayPlex is a high-throughput library screening application which was originally developed to find immunotherapy drugs for cancer. For the COVID-19 trials, ArrayPlex has been adapted and repurposed to allow 18,000 patient serum samples in one ‘library’ to be screened against a small protein library from the COVID-19 virus, SARS -Cov-2. Each week the platform will generate 1 ¼ million separate datapoints describing the immune profiles of 126,000 patients. This high-volume capacity to process population-scale samples is what makes this technique a ground-breaking achievement in the quest against COVID-19.

Iain McWilliam again;

“Screening 18000 patients in a 24-hour period is a considerable achievement but it’s a figure that is readily manageable with this technology. We are dealing with an extremely virulent strain of coronavirus, so it is important that the process is highly automated to reduce the risks of technical teams coming into contact with infectious samples.”  

Coronaviruses tend to induce weak immune responses, which means secondary infections of COVID-19 remain a distinct possibility, and therefore managing COVID-19 is a long-term problem. Arrayjet and CDI, with their Arrayplex COVID-19 antibody screening solution, are offering an innovative contribution to these challenges.

About Arrayjet 

Arrayjet is a leading providers of innovative microarray solutions to researchers, drug development groups and diagnostic companies across 27 countries world-wide.  Arrayjet is accredited to ISO13485 and provides CRO/CMO liquid handling solutions to support a variety of microarray applications. 

Offering a flexible, customer focussed approach with the provision of Arrayjet Advance™ microarray printing services in addition to a range of five scalable microarray printers, accessories & consumables.

Arrayjet's microarray printing technology uses a unique, non-contact, inkjet printhead that offers unrivalled speed, reproducibility and precision to deliver high quality microarrays faster than any other technology. 

www.arrayjet.com

Arrayjet is supported by investment from the Archangels business angel syndicate (www.archangelsonline.com) and Scottish Enterprise (www.scottish-enterprise.com).

About CDI

The CDI mission is to empower research and development in proteomics with proprietary technologies, making possible — today — the protein discoveries of tomorrow. CDI's HuProt™ protein microarrays and related services make it possible to perform rapid and efficient analyses of thousands of protein interactions using minimal amounts of valuable research or clinical samples.

The Company's microarray-powered monoclonal antibodies (MAbs] and MAb-related services provide unprecedented levels of specificity. Our system of antibody production is part of the NIH Protein Capture Reagents program and is currently working to produce truly mono-specific antibodies to human transcription factors. Website - https://cdi.bio/